Market analysis compares the financial performance and outlook of Northwest Biotherapeutics and Regeneron Pharmaceuticals.
2 reports, 1 independent
Updated Aug 26
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Market analysis compares the financial performance and outlook of Northwest Biotherapeutics and Regeneron Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Northwest Biotherapeutics
Development-stage American pharmaceutical company
Nothing else this week.
-
Regeneron Pharmaceuticals
American pharmaceutical company
Related events
- MarketBeat provided stock performance data and analyst recommendations for Regeneron Pharmaceuticals and IDEAYA Biosciences.
- The National Pension Service increased its stock holdings in Regeneron Pharmaceuticals.
- Regeneron Pharmaceuticals filed required reports with the SEC regarding institutional holdings on September 8, 2026.